DCB Funding Opportunity and Grants-Related Resources
DCB provides public resources related to notices of funding opportunities and NCI grant policies to cancer researchers.
"Getting a Grant from the NCI" Webinar
On April 21, 2022, Dr. Dan Gallahan (the Director of DCB) was joined by Drs. Joanna Watson (DCB Branch Chief), Amy Rubinstein (Review Branch Chief at the NIH Center for Scientific Review), and Shannon Hughes (DCB Deputy Director) for a special virtual session on NCI grant policies. It covered considerations for new and experienced applicants, as well as information about peer review.
New Grantee Workshop
DCB offers an annual workshop for new and early-stage investigators to familiarize them with the processes and standards of DCB, NCI and NIH. It is designed for DCB grantees who have received their first independent NIH grant within the last year.
It includes breakout sessions with DCB Program Directors and a seminar from an NCI-funded mid-career cancer researcher.
Below is the agenda and the presentations from the January 2023 Workshop (posted with permission from each author; please do not use without consent):
Session 1: The NCI and Your New Investigator Grant
- Introduction to the NIH Grants System and Division of Cancer Biology
- NCI Budget Processes - How is Grant Funding Policy Made?
- Communicating with Your NCI Program Director: It's a Two Way Street
- Post-Award Administration: An Overview for New Investigators
Session 2: Expanding Your Research Enterprise
Session 3: Review, Renew, and Promote Your Science
- Peer Review at NIH
- Review, Resubmission, and Renewals
- DCB/NCI Outreach Activities to Promote Science
Questions about the workshop should be directed to Dr. Joanna Watson.
Pre-application Webinar Materials Related to Funding Opportunities
|NOFO Title(s)||NOFO Number(s)||Webinar Date||Webinar Materials|
|Human Tumor Atlas (HTA) Research Centers (U01 Clinical Trial Not Allowed)||RFA-CA-23-039||11/09/2023||webinar slides, recording, and FAQs|
|Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (U01 Clinical Trial Not Allowed) &
Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed)
|RFA-CA-23-036 & RFA-23-037||08/11/2023||webinar slides, recording, and FAQs|
|Cancer Immunoprevention Network (CIP-Net) Research Projects (UG3/UH3 Clinical Trials Not Allowed)||RFA-CA-23-029||05/18/2023||webinar recording|
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
|PAR-19-113 & PAR-22-099||09/13/2016||webinar slides|